VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Bridged Bicyclo Compounds, Heterocyclic
Dasatinib
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Male
Middle Aged
Protein Kinase Inhibitors
Sulfonamides
Treatment Outcome
authors with profiles
ZEEV ESTROV
ALESSANDRA FERRAJOLI
YESID ALVARADO
ELIAS JOSEPH JABBOUR
GAUTAM BORTHAKUR
JAN ANDREAS BURGER
NITIN JAIN
NAVEEN PEMMARAJU
KIRAN NAQVI
KOICHI TAKAHASHI
PRITHVIRAJ BOSE
HAGOP M KANTARJIAN